Question 1
What is the primary therapeutic action of NMDA receptor antagonists in Alzheimer's treatment?
Question 2
What is the primary function of cholinesterase inhibitors in the treatment of Alzheimer's?
Question 3
Which drug class works by inhibiting the enzyme that breaks down acetylcholine?
Question 4
Which hypothesis of Alzheimer's disease highlights the role of abnormally folded beta-amyloid proteins?
Question 5
Which hypothesis describes Alzheimer's disease as being caused by the loss of central cholinergic neurons?
Question 6
What is a future target for Alzheimer's disease treatment focusing on beta-amyloid?
Question 7
What is the primary characteristic of Alzheimer's disease?
Question 8
Which hypothesis involves the abnormal aggregation of Tau proteins disrupting neuron transport systems?
Question 9
Memantine is commonly used to treat which condition?
Question 10
Rivastigmine inhibits which two enzymes?
Question 11
Which of the following side effects is commonly associated with Memantine?
Question 12
Which of the following is a common side effect of cholinesterase inhibitors?
Question 13
Alzheimer’s treatment focusing on Tau proteins aims to achieve which of the following?
Question 14
Challenges in developing new Alzheimer's treatments often include which of the following?
Question 15
Which of the following drugs is a cholinesterase inhibitor?